Spero posts Q4 net loss of $20.9M; revenue down 80% YoY; pipeline setbacks and SEC Wells Notice

Spero Therapeutics, Inc.

Net loss of $20.9M in Q4 2024 vs net income of $51.2M in Q4 2023; diluted EPS loss of $(0.38).
Total revenue fell to $15.0M from $73.5M YoY, driven by lower collaboration revenue from GSK and Pfizer.
Tebipenem HBr Phase 3 PIVOT-PO interim analysis expected Q2 2025; SPR720 Phase 2a missed primary endpoint with three cases of grade 3 hepatotoxicity; SPR206 discontinued.
Leadership change: Esther Rajavelu appointed Interim President and CEO in January 2025 following a Wells Notice from SEC related to disclosures in 2022.
Cash of $52.9M as of Dec 31, 2024; plus GSK milestones provide runway into Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.